CIMAher® (Nimotozumab)

CIMAher® (Nimotozumab) is a humanized monoclonal antibody used to treat head and neck squamous cell carcinomas, recurrent or refractory high-grade malignant gliomas, anaplastic astrocytomas and glioblastomas.

Nimotuzumab binds to a protein called epidermal growth factor receptor (EGFR), which is found on some types of normal cells and some types of cancer cells. Blocking this protein can help prevent cancer cells from forming.

Therapeutic indications

• Treatment of head and neck tumors in advanced stages in combination with radiotherapy and/or chemotherapy.
• Treatment of adult patients with highly malignant glial tumors: Glioblastoma multiforme and anaplastic astrocytoma, in combination with radiotherapy.
• Treatment of pediatric patients with newly diagnosed high-grade glial tumors in combination with radiotherapy and radiochemotherapy.
• Treatment of pediatric patients with recurrent or refractory glial tumors with nimotuzumab.
• Treatment of patients with non-operable malignant esophageal tumors of epithelial origin in combination with radiochemotherapy.
• Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas, in combination with chemotherapy.

Currently in the clinical research phase: cancer of the esophagus, colon, cervix, breast, anal canal, nasopharyngeal tumors, hepatocellular carcinoma, among others .

RELATED TREATMENTS

Lung Cancer Vaccines

Natural Products for Cancer